

## Antitrust Risks of Co-Promotion and Co-Marketing Agreements in Pharmaceutical Patent Settlements Around the World

SEPTEMBER 4, 2014

In the wake of FTC v. Actavis and the European Commission's decisions against Lundbeck, J&J and Novartis, pharma patent settlement agreements remain an issue in the US and Europe. Among questions yet to be resolved is how co-promotion and co-marketing, and manufacturing arrangements that are part of patent settlement agreements should be analyzed by antitrust enforcers.

WilmerHale Partner Mark Ford will be a featured speaker on this panel.

[READ MORE ABOUT THE EVENT](#)

---

### *Speakers*



**Mark A. Ford**

PARTNER

✉ [mark.ford@wilmerhale.com](mailto:mark.ford@wilmerhale.com)

📍 BOSTON

☎ + 1 617 526 6423

---

## *Related Solutions*

Antitrust and Competition

Intellectual Property  
Counseling and Prosecution

Intersection of Antitrust and  
P

## *You May Be Interested In*



### **Crypto Currently: Crypto Policy Updates**

APRIL 4, 2024

WEBINAR



### **31st Annual Fordham Intellectual Property Law & Policy Conference**

APRIL 4–5, 2024

SPEAKING ENGAGEMENT



## **CFTC 2023 Year in Review and a Look Forward Webinar**

APRIL 9, 2024

**WEBINAR**

[VIEW ALL EVENTS](#)